RedHill Biopharma reported $2.69M in EBITDA for its fiscal quarter ending in June of 2023.





Ebitda Change Date
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Clal Biotechnology ILS -5.3M 2.09M Dec/2022
Compugen USD -8.84M 180K Jun/2026
Cronos Group USD 17.08M 6.1M Sep/2026
RedHill Biopharma USD 2.69M 108.46M Jun/2023